Treatment group (n = 57) | Control group (n = 57) | |
---|---|---|
Age (years old) | ||
Mean | 69.0 | 71.6 |
Standard deviation | 11.6 | 10.8 |
Gender | ||
Male | 45 (79%) | 41 (72%) |
Female | 12 (21%) | 16 (28%) |
First treatment | ||
Yes | 49 (86%) | 53 (93%) |
No | 8 (14%) | 4 (7%) |
Type of amputation | ||
Digital | 49 (86%) | 49 (86%) |
Transmetatarsal | 8 (14%) | 8 (14%) |
Related pathologies | 53 (93%) | 57 (100%) |
Hypertension | 50 (88%) | 50 (88%) |
Chronic renal failure | 20 (35%) | 28 (49%) |
Hemodialysis | 6 (10%) | 1 (2%) |
Heart diseases | 35 (61%) | 43 (75%) |
Neurological disorders | 2 (4%) | 8 (14%) |
Autoimmune disorders | 1 (2%) | – |
Chronic respiratory failure | 9 (16%) | 14 (25%) |
Others | 9 (16%) | 10 (18%) |
Smoke | ||
Yes | 11 (20%) | 8 (14%) |
Former | 23 (40%) | 24 (42%) |
No | 23 (40%) | 25 (44%) |
Concomitant therapies | 57 (100%) | 57 (100%) |
Oral anticoagulant | 8 (14%) | 15 (26%) |
Antiplatelet | 53 (93%) | 53 (93%) |
Insulin | 37 (65%) | 46 (81%) |
OHAs | 32 (56%) | 25 (44%) |
NSAIDs | 8 (14%) | 9 (16%) |
Opioid | 6 (10%) | 7 (12%) |
Antibiotics | 10 (18%) | 6 (10%) |
Others | 7 (12%) | 3 (5%) |